TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $325,023 | -39.7% | 36,356 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $538,568 | -19.4% | 35,063 | +18.1% | 0.00% | -25.0% |
| Q1 2023 | $667,908 | +9.1% | 29,698 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $612,120 | -14.0% | 29,107 | +0.7% | 0.00% | -20.0% |
| Q3 2022 | $712,000 | +3.0% | 28,913 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $691,000 | -8.5% | 28,505 | -2.7% | 0.01% | +25.0% |
| Q1 2022 | $755,000 | -22.5% | 29,311 | -6.6% | 0.00% | -20.0% |
| Q4 2021 | $974,000 | +25.8% | 31,375 | -1.7% | 0.01% | +25.0% |
| Q3 2021 | $774,000 | +62.3% | 31,907 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $477,000 | -40.7% | 32,665 | +1.3% | 0.00% | -33.3% |
| Q1 2021 | $805,000 | +3.9% | 32,248 | +13.4% | 0.00% | 0.0% |
| Q4 2020 | $775,000 | – | 28,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |